Address: 504, Peninsula TowersPeninsula Corporate ParkGanpatrao Kadam Marg, Lower ParelIND – Mumbai 400 013,India
Tel: +91 22 40 49 11 11
At UCB our sense of purpose is to help people suffering from severe central nervous system or immunological disorders lead normal, everyday lives. Our ambition is to offer them innovative new medicines and ground-breaking solutions that go beyond the drug. We are committed to enabling cutting-edge scientific research that is driven by the patients’ needs.
UCB, headquartered in Brussels, Belgium, is a global biopharma company with a team of over 8500 talented employees, a strong market presence in more than 40 countries, € 3.2 billion in revenue (2010) and numerous strategic partnerships across the industry.
We combine biology and chemistry to make major breakthroughs.
By integrating our expertise in large, antibody-based molecules and small, chemically-derived molecules, we can offer families with severe diseases and their specialist physicians the advantages of both large and small molecules to produce extraordinary breakthroughs.
We partner with the leaders in the pharmaceutical industry.
The complexities of severe diseases are beyond the expertise and resources of a single organisation. That is why we have teamed up with partners – we play to our strengths and tap into the organisations with greater or complementary strengths.
UCB’s medicines are making a real difference to the lives of people all over the world. Some of our products are among the leaders in their field.
Restless Legs Syndrome
Regulating cerebral functions
Metadate CD™ (methylphenidate HCl) (CII)
Attention Deficit Hyperactivity Disorder (ADHD)
Cimzia® (certolizumab pegol)
Tussionex™ (hydrocodone polistirex and chlorpheniramine polistirex) (CIII)
Since the company’s foundation in 1993, Hetero has clearly come a long way. What were the key success factors at…
Over the years, multinational corporations (MNCs) have increasingly been penetrating the Indian pharmaceutical…
India is clearly a new location for Cockram, and what brought you here was your loyal customer Pfizer. After 3…
Dilip Surana of family-run Indian generics giant Micro Labs talks company performance, the evolution of the Indian…
Having been director here in India between 1998-2002, and then again since 2006, you have clearly been in the front…
You have very successfully executed a vision that you have had for the company since it was a 200 Rs Cr turnover,…
When Astellas announced to expand its presence in India in 2009, you were already speaking of the company’s…
What probably best explains the contrasts in the Indian pharmaceutical landscape is the fact that India can take…
You already joined the company in 2001, and returned after an MBA in the USA in 2004. This was also the time the…